Randomized clinical trials are required to confirm whether such agents would prevent adverse cardiovascular events in high-risk patients with MPN, although a preliminary study involving patients with CHIP enrolled in the CANTOS study reported that patients with TET2 mutations responded better to the anti-IL-1β antibody canakinumab than patients without CHIP-associated mutations [17]. This evidence concerns the gene TET2 and myeloproliferative disorder.